medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2022, Number 1

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2022; 20 (1)

Alopecias and COVID-19. What do we need to know?
Questionnaire

Briseño-Gascón G, Cano-Aguilar LE, Vega-Memije ME

Language: Spanish
References: 44
Page: 58-64
PDF size: 132.96 Kb.


ABSTRACT

Introduction: the extrapulmonary manifestations that are most frequently associated with COVID-19 disease are dermatological, of which alopecia has been little described despite being common during or after infection, as dermatologists we must be alert for recognition and treatment.
Objective: to know the different types of alopecia associated with a SARS-COV-2 infection reported in the literature.
Methods: the information search was carried out through PubMed, using different MeSH terms, with articles published in the period from March 2020 to June 2021.
Results: a total of 23 articles were obtained, some were found in more than one search criteria. Most of these articles mention telogen effluvium and androgenetic alopecia.
Conclusions: skin manifestations by SARS-COV-2 have been reported more frequently in recent months, being alopecia one of them. To date, a specific pattern of alopecia has not been recognized in patients with acute, late manifestations or sequelae derived from this disease. Cohorts and clinical trials are required to clarify the cutaneous manifestations that affect the skin appendages, including hair diseases.


REFERENCES

  1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The Lancet 2020; 395(10223):497-506.

  2. Marzano AV, Cassano N, Genovese G, Moltrasio C y Vena GA, Cutaneous manifestations in patients with covid-19: a preliminary review of an emerging issue, Br J Dermatol 2020; 183(3):431-42.

  3. Matar S, Oulès B, Sohier P, Chosidow O, Beylot-Barry M, Dupin N et al., Cutaneous manifestations in sars-cov-2 infection (covid-19): a French experience and a systematic review of the literature, J Eur Acad Dermatol Venereol 2020; 34(11):686-9.

  4. Genovese G, Moltrasio C, Berti E y Marzano AV, Skin manifestations associated with covid-19: current knowledge and future perspectives, Dermatology 2021; 237(1):1-12.

  5. Wollina U, Karadag˘ AS, Rowland-Payne C, Chiriac A y Lotti T, Cutaneous signs in covid-19 patients: a review, Dermatol Ther 2020; 33(5): 1-6.

  6. Guan W, Ni Z, Hu Y et al., Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med 2020; 30382(18):1708-20.

  7. Daneshgaran G, Dubin DP y Gould DJ, Cutaneous manifestations of covid-19: an evidence-based review, Am J Clin Dermatol 2020; 21(5):627-39.

  8. Phillips TG, Slomiany WP y Allison R, Hair loss: common causes and treatment, Am Fam Physician 2017; 96(6):371-8.

  9. Jafferany M y Patel A, Trichopsychodermatology: the psychiatric and psychosocial aspects of hair disorders, Dermatol Ther 2020; 33(1):131-4.

  10. Coleman E, Types and treatment of hair loss in men and women, Plast Surg Nurs 2020; 40(1):6-19.

  11. Asghar F, Shamim N, Farooque U, Sheikh H y Aqeel R, Telogen effluvium: a review of the literature, Cureus 2020; 12(5):1-7.

  12. Rebora A, Proposing a simpler classification of telogen effluvium, Skin Appendage Disord 2016; 2(1-2):35-8.

  13. Chien Yin GO, Siong-See JL y Wang ECE, Telogen effluvium: a review of the science and current obstacles, J Dermatol Sci 2021; 23:(21)1-8.

  14. Yavuz IH, Yavuz GO, Bilgili SG, Demir H y Demir C, Assessment of heavy metal and trace element levels in patients with telogen effluvium, Indian J Dermatol 2018; 63(3):246-50.

  15. Goren A, Vaño-Galván S, Wambier CG, McCoy J, Gómez-Zubiaur A, Moreno-Arrones OM, Shapiro J, Sinclair RD, Gold MH, Kovacevic M, Mesinkovska NA, Goldust M y Washenik K, A preliminary observation: male pattern hair loss among hospitalized covid-19 patients in Spain: a potential clue to the role of androgens in covid-19 severity, J Cosmet Dermatol 2020;19(7):1545-7.

  16. Trüeb RM y Dias MFRG, Alopecia areata: a comprehensive review of pathogenesis and management, Clin Rev Allergy Immunol 2018; 54(1): 68-87.

  17. Lee S y Lee WS, Management of alopecia areata: updates and algorithmic approach, J Dermatol 2017; 44(11):1199-211.

  18. Chelidze K y Lipner SR, Nail changes in alopecia areata: an update and review, Int J Dermatol 2018; 57(7):776-83.

  19. Rajabi F, Drake LA, Senna MM y Rezaei N, Alopecia areata: a review of disease pathogenesis, Br J Dermatol 2018; 179(5):1033-48.

  20. Kanwar AJ y Narang T, Anagen effluvium, Indian J Dermatol Venereol Leprol 2013; 79(5):604-12.

  21. Freites-Martínez A, Shapiro J, Goldfarb S, Nangia J, Jiménez JJ, Paus R y Lacouture ME, Hair disorders in patients with cancer, J Am Acad Dermatol 2019; 80(5):1179-96.

  22. Lolli F, Pallotti F, Rossi A, Fortuna MC, Caro G, Lenzi A, Sansone A y Lombardo F, Androgenetic alopecia: a review, Endocrine 2017; 57(1): 9-17.

  23. McCoy J, Wambier CG, Vaño-Galván S, Shapiro J, Sinclair R, Ramos PM, Washenik K, Andrade M, Herrera S y Goren A, Racial variations in covid-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for covid-19?, J Cosmet Dermatol 2020; 19(7):1542-3.

  24. Wambier CG, Vaño-Galván S, McCoy J, Gómez-Zubiaur A, Herrera S, Hermosa-Gelbard A, Moreno-Arrones OM, Jiménez-Gómez N, González-Cantero A, Fonda-Pascual P, Segurado-Miravalles G, Shapiro J, Pérez-García B y Goren A, Androgenetic alopecia present in the majority of patients hospitalized with covid-19: the “Gabrin sign”, J Am Acad Dermatol 2020; 83(2):680-2.

  25. Wambier CG, Vaño-Galván S, McCoy J, Pai S, Dhurat R y Goren A, Androgenetic alopecia in covid-19: compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign, J Am Acad Dermatol 2020; 83(6):453-4.

  26. Goren A, McCoy J, Wambier CG, Vano-Galván S, Shapiro J, Dhurat R, Washenik K y Lotti T, What does androgenetic alopecia have to do with covid-19? An insight into a potential new therapy, Dermatol Ther 2020; 33(4):1-2.

  27. Moreno-Arrones OM, Lobato-Berezo A, Gómez-Zubiaur A, Arias- Santiago S, Saceda-Corralo D, Bernárdez-Guerra C, Grimalt R, Fernández- Crehuet P, Ferrando J, Gil R, Hermosa-Gelbard A, Rodrigues- Barata R, Fernández-Nieto D, Merlos-Navarro S y Vañó-Galván S, sars-cov-2: induced telogen effluvium: a multicentric study, J Eur Acad Dermatol Venereol 2020; 35(3):181-3.

  28. Cline A, Kazemi A, Moy J, Safai B y Marmon S, A surge in the incidence of telogen effluvium in minority predominant communities heavily impacted by covid-19, J Am Acad Dermatol 2021; 84(3):773-5.

  29. Xerfan EMS, Andersen ML, Facina AS, Tufik S y Tomimori J, The role of sleep in telogen effluvium and trichodynia: a commentary in the context of the current pandemic, J Cosmet Dermatol 2021; 36(1):1-7.

  30. Domínguez-Santás M, Haya-Martínez L, Fernández-Nieto D, Jiménez- Cauhé J, Suárez-Valle A y Díaz-Guimaraens B, Acute telogen effluvium associated with sars-cov-2 infection, Aust J Gen Pract 2020; 49 (1):1-2.

  31. Rivetti N y Barruscotti S, Management of telogen effluvium during the covid-19 emergency: psychological implications, Dermatol Ther 2020; 33(4):1-5.

  32. Mieczkowska K, Deutsch A, Borok J, Guzmán AK, Fruchter R, Patel P, Wind O, McLellan BN, Mann RE y Halverstam CP, Telogen effluvium: a sequela of covid-19, Int J Dermatol 2021; 60(1):122-4.

  33. Rizzetto G, Diotallevi F, Campanati A, Radi G, Bianchelli T, Molinelli E, Mazzanti S y Offidani A, Telogen effluvium related to post severe sars-cov-2 infection: clinical aspects and our management experience, Dermatol Ther 2021; 34(1):1-16.

  34. Miyazato Y, Morioka S, Tsuzuki S, Akashi M, Osanai Y, Tanaka K, Terada M, Suzuki M, Kutsuna S, Saito S, Hayakawa K y Ohmagari N, Prolonged and late-onset symptoms of coronavirus disease 2019, Open Forum Infect Dis 2021; 7(11):1-16.

  35. Turkmen D, Altunisik N, Sener S y Colak C, Evaluation of the effects of covid-19 pandemic on hair diseases through a web-based questionnaire, Dermatol Ther 2020; 33(6):1-19.

  36. Olds H, Liu J, Luk K, Lim HW, Ozog D y Rambhatla PV, Telogen effluvium associated with covid-19 infection, Dermatol Ther 2021; 6:1-4.

  37. Trüeb RM, Dutra Rezende H y Gavazzoni Dias MFR, What can the hair tell us about covid-19?, Exp Dermatol 2021; 30(2)288-90.

  38. Fivenson D, covid-19: association with rapidly progressive forms of alopecia areata, Int J Dermatol 2021; 60(1):127.

  39. Rodríguez-Jiménez P, Ramírez-Bellver JL y Ruiz-Rodríguez R, Alopecia areata not due by isotretinoin. A thought in covid-19 time, Dermatol Ther 2020; 33(4):1.

  40. Alessandro C, Domenico G, Nazareno G, Georgios BC, Flavia P, Federica O y Severino P, Alopecia areata (aa) in a covid-19 patient: a case report, Dermatol Ther 2020; 16:1-3.

  41. Sgubbi P, Savoia F, Calderoni O, Longo R, Stinchi C y Tabanelli M, Alopecia areata in a patient with sars-cov-2 infection, Dermatol Ther 2020; 33(6):1-2.

  42. Kutlu Ö, Aktas ¸ H, I·mren IG y Metin A, Short-term stress-related increasing cases of alopecia areata during the covid-19 pandemic, J Dermatolog Treat 2020; 19:1.

  43. Turan Ç, Metin N, Utlu Z, Öner Ü y Kotan ÖS, Change of the diagnostic distribution in applicants to dermatology after covid-19 pandemic: what it whispers to us?, Dermatol Ther 2020; 33(4):1-3.

  44. Shanshal M, covid-19 related anagen effluvium, J Dermatolog Treat 2020; 16:1-2.




2020     |     www.medigraphic.com